Activating ALK alterations (mutations, amplifications, fusions/rearrangements) are found in various malignancies including, but not limited to, non-small lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL) (an uncommon, aggressive CD30-positive T-cell lymphoma comprising 0.5% of adult lymphomas and ~10% of non-Hodgkin lymphoma cases in children), inflammatory myofibroblastic tumors (IMT) (rare intermediate-grade neoplasms, generally found in children, which have a high recurrence rate after excision but with low metastatic potential), neuroblastomas, and inflammatory breast cancers. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.